<DOC>
	<DOCNO>NCT01199562</DOCNO>
	<brief_summary>RATIONALE : Infection prophylaxis management may help prevent cytomegalovirus ( CMV ) infection cause stem cell transplant . PURPOSE : This clinical trial study infection prophylaxis management treat cytomegalovirus infection patient hematologic malignancy previously treat donor stem cell transplant .</brief_summary>
	<brief_title>Infection Prophylaxis Management Treating Cytomegalovirus ( CMV ) Infection Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate efficacy safety individualize strategy cytomegalovirus ( CMV ) preemptive management , one monitor CMV viral load clinical marker immunosuppression optimize use ganciclovir recipient allogeneic hematopoietic cell transplantation ( HCT ) experience CMV reactivation . SECONDARY OBJECTIVES : I . To investigate donor killer-cell immunoglobulin-like receptor ( KIR ) gene interest ( activate KIR2DS2 2DS4 , inhibitory KIR2DL1 , 2DL2/2DL3 , 3DL1 , 3DL2 ) , together recipient ligand know , influence CMV reactivation-free survival allogeneic HCT , independently clinical risk factor onset acute graft-versus-host disease . II . To investigate whether marker natural killer ( NK ) cell function correlate ) KIR/ligand compound genotype baseline concurrent clinical factor b ) history CMV reactivation anti-CMV therapy time NK cell collection . III . To investigate association NK cell recovery antigen-specific T cell immune reconstruction . OUTLINE : Patients receive standard antiviral infection prophylaxis management comprise ganciclovir , valganciclovir , foscarnet sodium 2 week plasma CMV deoxyribonucleic acid ( DNA ) quantitative polymerase chain reaction ( Q-PCR ) negative . Patients may receive additional course base subsequent CMV reactivations . After completion study treatment , patient follow 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Leukemia , Neutrophilic , Chronic</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Leukemia , Mast-Cell</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Diagnosis : hematologic malignancies/disorders include aplastic anemia myelodysplastic syndrome Procedure : first allogeneic , T cellreplete transplantation stemcells peripheral blood bone marrow human leukocyte antigen ( HLA ) match , unrelated nonsyngeneic sibling donor CMV seropositive donor and/or recipient Performance level : must already determine eligible HCT City Hope ( COH ) Organ function requirement : The minimum organ function requirement requirement HCT Informed Consent : All patient must capable sign write informed consent consent provide legal guardian The recipient prior polymerase chain reaction ( PCR ) positive CMV infection blood organspecific disease past 12 month The source hematopoietic stem cell Tcell deplete Concomitant antigraftversushost disease ( GVD ) treatment include vivo T cell depletion Recipient human immunodeficiency virus ( HIV ) 1 positive No prior allogeneic HCT ( Allo HCT ) ( autologous HCT [ Auto HCT ] allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>